A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG)
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2016
Price : $35 *
At a glance
- Drugs HSV 1716 (Primary) ; Dexamethasone
- Indications Glioma
- Focus Adverse reactions; Biomarker
- 07 Jun 2016 Last checked against the ClinicalTrials.gov record.
- 26 May 2016 Status changed from recruiting to discontinued.
- 14 Jan 2014 New source identified and integrated ( ClinicalTrials.gov, NCT02031965)